Evaluation of Antiserum Level of EBV-VCA Antibodies in Acute Attack in Patients with Multiple Sclerosis View PDF

*Mohammad Aminianfar
Department Of Aerospace And Subaquatic Medicine, Infectious Diseases And Tropical Medicine Research Center, AJA University Of Medical Sciences, Tehran, Iran, Islamic Republic Of

*Corresponding Author:
Mohammad Aminianfar
Department Of Aerospace And Subaquatic Medicine, Infectious Diseases And Tropical Medicine Research Center, AJA University Of Medical Sciences, Tehran, Iran, Islamic Republic Of
Email:mohammaddarvishimd@yahoo.com

Published on: 2019-07-15

Abstract

Introduction: MS is considered as one of the most common causes of disability among young people. As no definite treatment has been recognized for this disease yet, the patients are confused due to the life struggles with regard to the chronic clinical conditions, influencing their quality of life and health. Thus, finding the factors exacerbating the MS and trying to eliminate these factors are crucial. Thus, this research was conducted to evaluate the antiserum level of EBV-VCA antibodies in an acute attack in patients with multiple sclerosis.
Method and Materials: In this descriptive, cross-sectional research, 30 patients with multiple sclerosis admitted to a neurologic clinic due to acute MS, were included. Anti-serum level of EBV-VCA antibodies was measured by the ELISA method.
Results: The research results revealed that out of total 30 patients, 3 patients (10%) had positive serum EBV-VCA IgM, 5 suspected cases (16.7%) were doubtful and 22 patients (73.3%) were negative in this regard. No significant relationship was found between serum level of EBV-VCA IgG and acute MS attack (P>0.05).
Conclusion: The results of the research and comparison of these results with those of some other studies suggest that there is no significant relationship between serum level of IgM EB-VCA and acute attack of multiple sclerosis.

Keywords

Multiple Sclerosis; EBV; MS attack; EB-VCA IgM

Introduction

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disorder of the central nervous system. This disease is one of the most common neurological diseases. It has four main patterns (relapsing-recovering), (progressive-secondary), (primary- progressive), (relapsing-progressive) [1].
MS is clinically defined as the involvement of different parts of the central nervous system at different times, provided that other multifocal diseases of the central nervous system are excluded. The first symptoms usually emerge before the age of 55, its peak is seen between the ages of 20 and 40, and its prevalence in women is two times more than that in men [2]. The myelin layer is attacked by the immune system in this disease, leading to lesions of the nervous system, axonal degeneration and brain atrophy [3]. Multiple sclerosis symptoms include paresthesia, dysfunction in walking, reduced or loss of vision, diplopia, etc. [2]. In some types of MS, patients often experience exacerbated and mitigated (relapsing and suppression) symptoms due to the process of inflammatory demyelination and axonal degeneration, and inadequate structural restoration and improvement in function. Symptoms of this disease are periodical in patients [4].

scroll up